



Beiträge der AGO Studiengruppe auf dem ASCO 2017

2. – 6. Juni 2017 Chicago / USA

AGO Leading Group

Freitag, 2. Juni 2017 Gynecologic Cancer

3:00 PM - 6:00 PM Oral Abstract Session

Location: S406

LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial.

Abstract 5500

P. Harter, J. Sehouli, D. Lorusso, A. Reuss, I. Vergote, C. Marth, J. W. Kim, F. Raspagliesi, B. Lampe, F. Landoni, W. Meier, D. Cibula, A. Mustea, S. Mahner, I. B. Runnebaum, B. Schmalfeldt, A. Burges, R. Kimmig, U. A. Wagner, A. du Bois

Randomized controlled phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – AGO DESKTOP III/ENGOT OV20

Abstract 5501

A. du Bois, I. Vergote, G. Ferron, A. Reuss, W. Meier, S. Greggi, P. Jensen, F. Selle, F. Guyon, C. Pomel, F. Lecuru, R. Zhang, E. Avall-Lundqvist, J. W. Kim, J. Ponce, F. Raspagliesi, S. Ghaem Maghami, A. Reinthaller, P. Harter, J. Sehouli

AGO Participating Group

Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.

Abstract 5507

M. Friedlander, V. GebSKI, E. Gibbs, R. Bloomfield, F. Hilpert, L. B. Wenzel, F. Joly, D. Eek, M. Rodrigues, A. R. Clamp, R. T. Penson, D. M. Provencher, J. Korach, T. Huzarski, L. Vidal, V. Salutarì, C. L. Scott, M. O. Nicoletto, K. Tamura, E. Pujade-Lauraine



Samstag, 3. Juni 2017 Gynecologic Cancer

1:15 PM - 4:45 PM Poster Session UND 4:45 PM - 6:00 Poster Discussion Session

Location: Hall A

Arie Crown Theater

AGO Leading Group

Board 343 / Abstract 5521

The prognostic value of tumor residuals (TR) indicated by surgeon (SA), by radiology (RA) or an integrated approach (IA) by surgeons' assessment and pre-chemotherapy CT-scan in patients with advanced ovarian cancer (AOC): An exploratory analysis of the AGO Study led Intergroup trial AGO-OVAR 12

F. Heitz, P. Harter, E. Avall-Lundqvist, A. Reuss, P. Pautier, G. Cormio, N. Colombo, J. Hell, I. Vergote, A. Poveda, P. Ottevanger, L. Hanker, J. Mäenpää, J. Alexandre, U. Canzler, J. Herrstedt, B. Fiane, J. Sehouli, M. Merger, A. du Bois

AGO Participating Group

4:45 PM - 6:00 Poster Discussion Session

Board 339 / Abstract 5517

Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.

M. R. Mirza, B. J. Monk, M. Gil-Martin, L. Gilbert, U. Canzler, P. Follana, J. S. Waters, F. Kridelka, T. Levy, B. B. Benigno, K. Woie, D. M. Provencher, H. Lueck, A. Casado Herraiz, A. Lesoin, J. Buscema, K. Hellman, B. Rimel, S. Hazard, U. A. Matulonis

AGO Participating Group

4:45 PM - 6:00 Poster Discussion Session

Board 340 / Abstract 5518

Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.

J. A. Ledermann, A. Lortholary, R. T. Penson, E. Gibbs, D. M. Provencher, I. Bruchim, T. Huzarski, M. Barretina-Ginesta, R. Sabbatini, L. R. Mileshkin, N. Colombo, T. Park-Simon, K. Matsumoto, G. S. Sonke, O. N. Mikheeva, J. Kim, G. C. Giotto, H. Denys, E. S. Lowe, E. Pujade-Lauraine

AGO Leading Group

Board 368 / Abstract 5546

BRCA-like classification in ovarian cancer – Results from AGO-TR1-trial

L. Richters, P. C. Schouten, S. Kommoss, J. Hauke, A. Burges, D. Dietrich, A. El-Balat, F. Hilpert, R. Kluin, M. Heubner, K. Kast, A. Heimbach, E. Braicu, S. Kroeber, K. Baumann, C. Jackisch, S. C. Linn, R. Schmutzler, P. Harter, E. Hahnen

Ausgezeichnet mit dem Merit Award.

Board 376 / Abstract 5554

2 major prognostic populations of ovarian cancer patients defined by CA-125 modeled kinetic parameter KELIM (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/GCIG trials).

B. You, O. Colombari, G. Feyer, A. Leary, I. L. Ray-Coquard, A. Lortholary, A. Hardy Bessard, J. Pfisterer, A. du Bois, C. Kurzedder, A. Burges, M. Tod



Board 423a / Abstract TPS5602

TRUST – Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO-OVAR OP7).

S. Mahner, F. Heitz, A. Burges, A. Reuss, B. Krämer, B. Schmalfeldt, J. Sehouli, B. Lampe, A. Schnelzer, P. Wimberger, C. Fotopoulou, F. Guyon, F. Lecuru, D. Querleu, S. Greggi, N. Colombo, G. Aletti, P. Harter, A. du Bois

AGO Participating Group

Board 356 / Abstract 5534

Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).

U. A. Matulonis, J. Herrstedt, A. Tinker, F. Marme, A. Redondo, E. Kalbacher, J. A. Ledermann, J. Pikiel, R. d. Christensen, J. S. Berek, T. Juhler-Nøttrup, A. M. Oza, W. Meier, M. Gil-Martin, A. Hardy-Bessard, B. J. Monk, P. Rosenberg, R. M. Wenham, S. Hazard, M. R. Mirza

Board 382 / Abstract 5560

The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC). (Abstract 5560)

J. Del Campo, M. R. Mirza, J. S. Berek, D. M. Provencher, G. Emons, M. Fabbro, R. Lord, N. Colombo, E. Petru, R. M. Wenham, J. Herrstedt, L. Gilbert, M. L. Heubner, A. Gonzalez Martin, P. Follana, B. B. Benigno, A. Dørum, B. Rimel, S. Hazard, U. A. Matulonis

Board 397 / Abstract 5575

Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥ 3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).

F. Roncolato, F. Joly, R. O'Connell, A. Lanceley, F. Heitz, L. Buizen, A. Okamoto, E. Aotani, V. Salutati, P. P. Donnellan, A. M. Oza, E. Avall-Lundqvist, J. S. Berek, F. Hilpert, A. Feeney, C. Roemer-Becuwe, M. R. Stockler, M. T. King, M. Friedlander

Board 424b / Abstract TPS5605

PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. (Abstract TPS5605)

I. L. Ray-Coquard, P. Harter, A. Gonzalez Martin, C. Cropet, S. Pignata, K. Fujiwara, C. Marth, I. Vergote, M. R. Mirza, N. Colombo, P. Rosenberg, J. U. Maenpaa, E. Pujade Lauraine